Novel Antidepressant Drugs, Arterial Hypertension and Cardiovascular Disease

Volume , Issues,

Aims & ScopeAbstracted/Indexed in

View Full Editorial Board

Novel Antidepressant Drugs, Arterial Hypertension and Cardiovascular Disease

Author(s): Vasiliki K. Katsi, Maria Marketou, Georgia Vamvakou, Thomas Makris, Dimitris Tousoulis, Christodoulos I. Stefanadis, Panos Vardas and Ioannis E. Kallikazaros

Affiliation: Cardiology Department, Hippokration Hospital, Greece, Vas. Sofias Avenue 114, Post code: 11527, Athens, Greece.


Depression is a common mental health issue worldwide leading to disability, functional decline and increased mortality. Novel antidepressants have been developed during the last decades in order to treat depression syndromes. Some evidence suggests that major depression has been associated with the development of congestive heart failure and with adverse outcomes in patients with coronary heart disease. The purpose of the present article is to review the impact of novel antidepressant patent drugs on cardiovascular disease and arterial hypertension.

Keywords: Arterial hypertension, bupropion, cardiovascular disease, depression, fluoxetine, norepinephrine reuptake inhibitors, serotonin reuptake inhibitors.

Purchase Online Order Reprints Order Eprints Rights and Permissions


Article Details

Volume: 8
Issue Number: 3
First Page: 178
Last Page: 185
Page Count: 8
DOI: 10.2174/1574890109666140407154738

Webmaster Contact: Copyright © 2015 Bentham Science